1] Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan [2] Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Br J Cancer. 2013 Sep 17;109(6):1693-8. doi: 10.1038/bjc.2013.503. Epub 2013 Sep 3.
For patients with breast cancer treated with preoperative chemotherapy, residual tumour burden in lymph nodes is the strongest prognostic factor. However, conventional pathological examination has limitations that hinder the accurate and reproducible measurement. The one-step nucleic acid amplification (OSNA) assay is a novel molecular method for detecting nodal metastasis. In this prospective multicentre trial, we assessed the performance of the OSNA assay in detecting nodal metastasis after chemotherapy.
In total, 302 lymph nodes from 80 breast cancer patients who underwent axillary dissection after chemotherapy were analysed. Each node was cut into two or four slices. One piece or alternate pieces were evaluated by pathology, and the other(s) were examined using the OSNA assay. The results of the two methods were compared. Stromal fibrosis, histiocytic aggregates, and degenerated cancer cells were regarded as chemotherapy-induced histological changes.
The overall accuracy, sensitivity, and specificity of the OSNA assay compared with the reference pathology were 91.1%, 88.3%, and 91.7%, respectively. Of the 302 lymph nodes, 66 (21.9%) exhibited chemotherapy-induced histology. For these nodes, the accuracy, sensitivity, and specificity were 90.9%, 88.9%, and 93.3%, respectively.
The OSNA assay can detect the residual tumour burden as accurately as conventional pathology, although chemotherapy-induced histological changes are present.
对于接受术前化疗的乳腺癌患者,淋巴结中的残留肿瘤负担是最强的预后因素。然而,常规的病理检查存在局限性,阻碍了准确和可重复的测量。一步法核酸扩增(OSNA)检测是一种用于检测淋巴结转移的新型分子方法。在这项前瞻性多中心试验中,我们评估了 OSNA 检测在化疗后检测淋巴结转移中的性能。
共分析了 80 例接受化疗后腋窝清扫术的乳腺癌患者的 302 个淋巴结。每个淋巴结被切成两到四片。一片或交替片进行病理评估,另一片或交替片使用 OSNA 检测。比较两种方法的结果。间质纤维化、组织细胞聚集和退化的癌细胞被视为化疗诱导的组织学变化。
OSNA 检测与参考病理相比的总体准确率、灵敏度和特异性分别为 91.1%、88.3%和 91.7%。在 302 个淋巴结中,有 66 个(21.9%)显示化疗诱导的组织学变化。对于这些淋巴结,准确率、灵敏度和特异性分别为 90.9%、88.9%和 93.3%。
尽管存在化疗诱导的组织学变化,但 OSNA 检测可以像常规病理一样准确地检测残留肿瘤负担。